- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.05. | FDA approves Selarsdi injection as interchangeable with Stelara | ||
| 05.05. | Chinese regulator grants priority review for InnoCare's solid tumour treatment | ||
| 05.05. | FDA accepts Novo Nordisk's NDA submission for weight management therapy | ||
| 02.05. | Q1 earnings pulse check: companies tentative on pharma-specific tariffs | ||
| 02.05. | MHRA authorises Bavarian Nordic's chikungunya virus vaccine | ||
| 02.05. | Entering the era of prenatal gene therapies | ||
| 02.05. | HHS launches $500m universal vaccines initiative | ||
| 02.05. | FDA awards RMAT status to 4DMT diabetic macular oedema therapy | ||
| 02.05. | PTSD market expected to reach $5.5bn across the 7MM by 2034 | ||
| 02.05. | Repare signs out-licensing deal with DCx Biotherapeutics | ||
| 01.05. | Biogen's Q1 revenue soars past estimates as rare disease pivot pays off | ||
| 01.05. | Lilly's Q1 2025 revenue jumps 45%, but CVS shift boosts Novo's Wegovy | ||
| 01.05. | New £1bn cancer research hub planned for South London | ||
| 01.05. | Dimerix and Amicus to commercialise DMX-200 in US | ||
| 01.05. | End-to-end solutions: why every link in the pharmaceutical supply chain counts | ||
| 01.05. | GSK remains resilient on tariffs as Q1 sales rise 4% | ||
| 01.05. | Novartis to strengthen renal disease portfolio with Regulus | ||
| 01.05. | FDA approves J&J's Imaavy for generalised myasthenia gravis | ||
| 01.05. | Investors insist halted biotech IPOs will return in 2025 | ||
| 30.04. | Biopharma venture financing declines 20.2% YOY in Q1 2025 amid persistent investor caution | ||
| 30.04. | Boehringer, Oxford University and Cumulus to explore brain activity in BPD | ||
| 30.04. | Trump's first 100 days tout US-bound pharma investments amid tariff worries | ||
| 30.04. | Donald Trump's first 100 days: Impact on the healthcare industry | ||
| 30.04. | Magazine: The GLP-1 shortage is over. What's next for compounders? | ||
| 30.04. | FDA approves AbbVie's upadacitinib for giant cell arteritis |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .